Brain Radiation with Dalpiciclib for Advanced Breast Cancer
Treatments studied
Part of Brain & nervous system, Cancer, Skin clinical trials.
This trial tests whether combining brain radiation therapy with two medications—dalpiciclib (a cell-cycle inhibitor) and hormone therapy—can help women with hormone-receptor-positive breast cancer that has spread to the brain. The goal is to shrink brain tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Female, aged 18–75, and postmenopausal or willing to take an LHRH agonist (a hormone injection) if still menstruating
- Diagnosed with HR-positive, HER2-negative breast cancer with spread to the brain (not suitable for surgery or standard chemotherapy)
- At least one brain tumor ≥1 cm visible on MRI scan
- Good overall health (ECOG performance status 0–2) with expected survival of at least 12 weeks
- Normal blood counts and organ function (kidney, liver, heart) based on recent lab tests
- No prior whole-brain radiation, severe brain symptoms, leptomeningeal disease, or serious uncontrolled infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
This study tests whether adding a new drug called dalpiciclib to standard hormone therapy improves outcomes for women with early-stage breast cancer that is hormone-receptor positive. The goal is to see if this combination is more effective and safe than hormone therapy alone.
This trial tests a new combination of oral hormone therapy (an aromatase inhibitor) plus a CDK4/6 inhibitor (dalpiciclib) for women with early-stage but locally advanced (Stage II–III) hormone receptor-positive, HER2-negative breast cancer. The goal is to shrink the tumor before surgery, potentially improving outcomes.
This trial tests a combination of three drugs (dalpiciclib, letrozole, and anlotinib) given before surgery to postmenopausal women with stage II or III HR+/HER2- breast cancer. The goal is to see if this neoadjuvant treatment shrinks tumors and improves outcomes.
This study tests whether combining two drugs (dalpiciclib and SHR-A1811) before surgery can shrink early-stage breast cancers that are hormone-sensitive and HER2-low. The goal is to see if this approach improves outcomes for patients with intermediate-to-high risk disease.
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.